BIOMAT Database Logo BIOMAT Database Logo

PAF and airway hyperreactivity. 1985

J Morley, and C P Page, and S Sanjar

UI MeSH Term Description Entries
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D001980 Bronchi The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI. Primary Bronchi,Primary Bronchus,Secondary Bronchi,Secondary Bronchus,Tertiary Bronchi,Tertiary Bronchus,Bronchi, Primary,Bronchi, Secondary,Bronchi, Tertiary,Bronchus,Bronchus, Primary,Bronchus, Secondary,Bronchus, Tertiary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas

Related Publications

J Morley, and C P Page, and S Sanjar
PAF and airway hyperreactivity; prospects for novel prophylactic anti-asthma drugs.
January 1987, Agents and actions. Supplements,
J Morley, and C P Page, and S Sanjar
PAF antagonism as an approach to the treatment of airway hyperreactivity.
March 1991, The American review of respiratory disease,
J Morley, and C P Page, and S Sanjar
The effect of prophylactic anti-asthma drugs on PAF-induced airway hyperreactivity.
October 1989, Japanese journal of pharmacology,
J Morley, and C P Page, and S Sanjar
[Airway hyperreactivity].
January 2011, Ceskoslovenska fysiologie,
J Morley, and C P Page, and S Sanjar
Airway hyperreactivity.
July 1988, Lancet (London, England),
J Morley, and C P Page, and S Sanjar
RP 59227, a novel PAF receptor antagonist: effects in guinea pig models of airway hyperreactivity.
January 1992, European journal of pharmacology,
J Morley, and C P Page, and S Sanjar
[Airway hyperreactivity and airway epithelial function].
May 1989, Kokyu to junkan. Respiration & circulation,
J Morley, and C P Page, and S Sanjar
Sympathomimetics and airway hyperreactivity.
November 1994, Thorax,
J Morley, and C P Page, and S Sanjar
Gold nanoparticles and airway hyperreactivity.
August 2011, The European respiratory journal,
J Morley, and C P Page, and S Sanjar
Mucosal oedema and airway hyperreactivity.
June 1989, The European respiratory journal. Supplement,
Copied contents to your clipboard!